Company intelligence / Profile preview
CereMark Pharma
Wheeling, West Virginia, United Statesceremarkpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CereMark Pharma is preparing for pivotal Phase 3 clinical trials of F-18 Flornaptitril, which has demonstrated in research the ability to simultaneously target and image both tau aggregates and beta-amyloid plaques associated with neurodegenerative diseases. Previous clinical studies have shown unique imaging capabilities on PET scans. The Phase 3 trial is planned to begin in late 2024.
- Therapeutic areas
- Neurology
- Modalities
- PET imaging radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Hall of Fame HealthInvicroSpectronRxUCLA
Beyond the preview
Go deeper on CereMark Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CereMark Pharma.